Non-Hodgkin Lymphoma Clinical Trials

49 recruiting

Non-Hodgkin Lymphoma Trials at a Glance

125 actively recruiting trials for non-hodgkin lymphoma are listed on ClinicalTrialsFinder across 6 cities in 33 countries. The largest study group is Phase 1 with 67 trials, with the heaviest enrollment activity in Houston, New York, and Duarte. Lead sponsors running non-hodgkin lymphoma studies include City of Hope Medical Center, Mayo Clinic, and Baylor College of Medicine.

Browse non-hodgkin lymphoma trials by phase

Treatments under study

About Non-Hodgkin Lymphoma Clinical Trials

Looking for clinical trials for Non-Hodgkin Lymphoma? There are currently 49 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Non-Hodgkin Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Non-Hodgkin Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 125 trials

Recruiting
Phase 1

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Non-Hodgkin LymphomaLymphoma
National Cancer Institute (NCI)55 enrolled1 locationNCT04739813
Recruiting
Phase 1Phase 2

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

Recurrent T-Cell Non-Hodgkin LymphomaRefractory T-Cell Non-Hodgkin Lymphoma
Fred Hutchinson Cancer Center50 enrolled1 locationNCT07225985
Recruiting
Phase 1Phase 2

Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

Recurrent B-Cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center30 enrolled1 locationNCT07283679
Recruiting
Phase 1

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Non-Hodgkin LymphomaPlasmablastic LymphomaBurkitt Lymphoma+2 more
National Cancer Institute (NCI)25 enrolled1 locationNCT05389423
Recruiting
Phase 2

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell LymphomaRefractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified+5 more
City of Hope Medical Center43 enrolled3 locationsNCT07365306
Recruiting
Phase 1Phase 2

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines614 enrolled127 locationsNCT05006716
Recruiting
Phase 2

Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

Indolent B-Cell Non-Hodgkin LymphomaRecurrent Indolent Non-Hodgkin LymphomaRefractory Indolent Non-Hodgkin Lymphoma+2 more
Mayo Clinic112 enrolled7 locationsNCT06386315
Recruiting
Phase 1

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma
Hoffmann-La Roche121 enrolled26 locationsNCT05169515
Recruiting
Phase 1Phase 2

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

Non-Hodgkin LymphomaLymphoma
National Cancer Institute (NCI)155 enrolled1 locationNCT03223610
Recruiting
Phase 1Phase 2

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

Hodgkin LymphomaNon-Hodgkin LymphomaLymphoma+4 more
AstraZeneca161 enrolled33 locationsNCT06137144
Recruiting
Phase 2

CAR T-cell Therapy in Patients With Renal Dysfunction

Multiple MyelomaAcute Lymphoblastic Leukemia, AdultNon-hodgkin Lymphoma,B Cell
Northside Hospital, Inc.20 enrolled1 locationNCT05909059
Recruiting
Phase 1Phase 2

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+6 more
BeiGene146 enrolled29 locationsNCT05294731
Recruiting
Phase 1Phase 2

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

Relapsed/Refractory Non-Hodgkin Lymphoma
Bristol-Myers Squibb308 enrolled65 locationsNCT06090539
Recruiting
Phase 1Phase 2

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

Diffuse Large B Cell LymphomaHodgkin LymphomaMantle Cell Lymphoma+6 more
New York Medical College20 enrolled1 locationNCT04491370
Recruiting
Phase 1

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

Recurrent Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaRecurrent Non-Hodgkin Lymphoma+12 more
Ohio State University Comprehensive Cancer Center24 enrolled1 locationNCT07166419
Recruiting
Phase 1

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

Recurrent B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma+3 more
National Cancer Institute (NCI)32 enrolled9 locationsNCT05272384
Recruiting
Phase 1

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

HIV InfectionRecurrent Non-Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma+11 more
AIDS Malignancy Consortium20 enrolled6 locationsNCT05077527
Recruiting
Phase 2

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma
Genmab496 enrolled75 locationsNCT05283720
Recruiting
Phase 1

KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Non-Hodgkin Lymphoma
TCRx Therapeutics Co.Ltd18 enrolled1 locationNCT07260812
Recruiting
Not Applicable

The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients

Indolent Non-hodgkin LymphomaChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Mayo Clinic70 enrolled2 locationsNCT05876923